Literature DB >> 11331079

Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers.

C Bizzarri1, S Pagliei, L Brandolini, P Mascagni, G Caselli, P Transidico, S Sozzani, R Bertini.   

Abstract

Although it is commonly accepted that the anti-inflammatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) is mainly associated to their ability to inhibit the cyclooxygenase (COX) enzyme system, several results indicate that non-COX mechanisms could be important in the therapeutical effect of these drugs. The aim of this study was to define if NSAIDs could exert, at least in part, their anti-inflammatory effect by inhibiting the activities of human polymorphonuclear leukocytes (PMNs) triggered by chemotactic stimuli and, if so, to understand the relationship of this effect with COX inhibition. A unique opportunity to dissociate the inhibition of prostaglandin (PG) synthesis from other therapeutical properties of NSAIDs is constituted by ketoprofen isomers being the S-isomer 100 time more potent than R-isomer on COX inhibition. Our results show that R- and S-ketoprofen, independently of their potency as PG inhibitors, proved very efficacious in selective inhibition of interleukin-8 (IL-8) chemotaxis. Inhibition of IL-8 chemotaxis was not restricted to ketoprofen isomer as it could be observed also with drugs belonging to different classes of NSAIDs and it was obtained at drug concentration superimposable to plasma levels after therapeutic administration in patients. Reduction of IL-8 migration by ketoprofen isomers was paralleled by selective inhibition of PMN response in terms of intracellular calcium concentration ([Ca(2+)]i) increase and extracellular signal regulated kinase(ERK)-2 activation, two intracellular mediators reported to be critical for PMN activities. It is concluded that inhibition of IL-8 chemotaxis could represent a new clinical target for ketoprofen isomers and, in fact, contribute to the anti-inflammatory activity of NSAIDs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331079     DOI: 10.1016/s0006-2952(01)00610-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Authors:  Danielle G Souza; Riccardo Bertini; Angelica T Vieira; Fernando Q Cunha; Steve Poole; Marcello Allegretti; Francesco Colotta; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

2.  Impaired neutrophil migration associated with specific bovine CXCR2 genotypes.

Authors:  M Rambeaud; G M Pighetti
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase.

Authors:  Huapeng Fan; Pam Hall; Leilani L Santos; Julia L Gregory; Gunter Fingerle-Rowson; Richard Bucala; Eric F Morand; Michael J Hickey
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

4.  Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief.

Authors:  Alessio Moriconi; Thiago M Cunha; Guilherme R Souza; Alexandre H Lopes; Fernando Q Cunha; Victor L Carneiro; Larissa G Pinto; Laura Brandolini; Andrea Aramini; Cinzia Bizzarri; Gianluca Bianchini; Andrea R Beccari; Marco Fanton; Agostino Bruno; Gabriele Costantino; Riccardo Bertini; Emanuela Galliera; Massimo Locati; Sérgio H Ferreira; Mauro M Teixeira; Marcello Allegretti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

Review 5.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

6.  Key role of proline-rich tyrosine kinase 2 in interleukin-8 (CXCL8/IL-8)-mediated human neutrophil chemotaxis.

Authors:  Vito Di Cioccio; Raffaele Strippoli; Cinzia Bizzarri; Giulia Troiani; Maria Neve Cervellera; Isabelle Gloaguen; Antonella Colagrande; Elisa Margherita Cattozzo; Sabrina Pagliei; Angela Santoni; Francesco Colotta; Fabrizio Mainiero; Riccardo Bertini
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

7.  Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.

Authors:  T M Cunha; M M Barsante; A T Guerrero; W A Verri; S H Ferreira; F M Coelho; R Bertini; C Di Giacinto; M Allegretti; F Q Cunha; M M Teixeira
Journal:  Br J Pharmacol       Date:  2008-03-24       Impact factor: 8.739

8.  Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.

Authors:  Riccardo Bertini; Marcello Allegretti; Cinzia Bizzarri; Alessio Moriconi; Massimo Locati; Giuseppe Zampella; Maria N Cervellera; Vito Di Cioccio; Maria C Cesta; Emanuela Galliera; Fernando O Martinez; Rosa Di Bitondo; Giulia Troiani; Vilma Sabbatini; Gaetano D'Anniballe; Roberto Anacardio; Juan C Cutrin; Barbara Cavalieri; Fabrizio Mainiero; Raffaele Strippoli; Pia Villa; Maria Di Girolamo; Franck Martin; Marco Gentile; Angela Santoni; Daniela Corda; Giuseppe Poli; Alberto Mantovani; Pietro Ghezzi; Francesco Colotta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-28       Impact factor: 11.205

9.  CXCR2: From Bench to Bedside.

Authors:  Anika Stadtmann; Alexander Zarbock
Journal:  Front Immunol       Date:  2012-08-24       Impact factor: 7.561

10.  The effect of ketoprofen in chronic periodontitis: A clinical double-blind study.

Authors:  M Srinivas; Sangeetha Medaiah; S Girish; M Anil; Jagadish Pai; Amit Walvekar
Journal:  J Indian Soc Periodontol       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.